Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning in children with achondroplasia on once-weekly navepegritide (TransCon CNP), 26-week Phase 2 data on a combination of TransCon CNP plus once-weekly lonapegsomatropin (TransCon hGH), and 214-week outcomes showing sustained improvements in skeletal dynamics in adults with chronic hypoparathyroidism on palopegteriparatide (TransCon PTH).
The company’s ASBMR 2025 slate focuses on endpoints beyond linear growth, including alignment, functional performance, and long-term skeletal remodeling. The achondroplasia readouts include a new analysis from the ApproaCH pivotal program, as well as the first congress presentation from the COACH combination study. The hypoparathyroidism update extends continuous observation past four years from the PaTH Forward program. All three will be delivered as oral sessions in Seattle.
Strategically, the package signals a deliberate pivot to clinically meaningful outcomes that resonate with regulators and payers, not just velocity metrics. In achondroplasia, linking changes in leg bowing to functional status strengthens the value proposition in a landscape already anchored by an approved CNP analog and growing emphasis on real-world benefits, such as mobility, pain relief, and surgery avoidance. The combination approach seeks to layer disproportionate correction from CNP on top of growth optimization from hGH. Still, it will need to demonstrate additive, clinically relevant benefits that justify the increased trial complexity and future treatment management. In hypoparathyroidism, durable skeletal dynamics data aim to underpin the positioning of chronic hormone replacement, addressing lingering questions about long-term bone quality, renal safety, and sustained control of calcium-phosphate homeostasis.
For sites and CROs, these programs raise the operational bar. Pediatric achondroplasia studies now lean on standardized radiographic alignment assessments, functional tests, and central reads, increasing imaging logistics, QA, and training demands. Combination therapy introduces protocol complexity around scheduling, concomitant medication rules, and safety monitoring for overlapping adverse events, though once-weekly dosing for both agents helps contain visit burden. Adult hypoparathyroidism programs emphasize long-duration follow-up with regimented lab monitoring and bone endpoints, favoring sites with stable longitudinal cohorts and robust data continuity processes. Vendors supporting digital gait analysis, patient-reported outcomes, and centralized imaging can expect heightened demand as sponsors seek validated tools to translate skeletal changes into functional benefit.
The regulatory and access implications are clear. Agencies have been encouraging sponsors to focus on outcomes tied to daily functioning and longer-term skeletal health, and HTA bodies are increasingly discounting centimeter-only narratives. If ApproaCH establishes a reproducible link between alignment correction and functional gains, expect those measures to surface as key secondaries or even co-primaries in future protocols and to feature prominently in payer dossiers. For the combination strategy, acceptance will hinge on a convincing efficacy delta without a safety or adherence penalty; drug-drug interaction characterization and pediatric risk management plans will be scrutinized. Long-term TransCon PTH data support chronic use; however, regulators and payers will closely monitor renal endpoints, hypercalcemia excursions, and fracture signals as exposure accumulates.
What to watch next: the Phase 3 design choices for TransCon CNP, including whether functional outcomes move forward as decision-driving endpoints; whether the CNP+hGH combination advances into a registrational path or is positioned for specific subgroups; and how long-term skeletal dynamics from TransCon PTH translate into label language and payer contracting. Competitive dynamics in achondroplasia may pressure sponsors toward head-to-head or at least harmonized outcome frameworks to enable credible indirect comparisons. Operationally, the field is moving toward integrated functional assessments and centralized imaging as standard infrastructure—sites that build these capabilities early will be advantaged as the bar for meaningful endpoints continues to rise.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
